


**Amendments to the Specification:**

Please delete the paragraphs beginning on page 17, line 14, and ending on page 19, line 13, and replace with the following paragraphs:


Preferred specific examples of an LH-RH agonist other than leuporelin mentioned above include:

(1) Buserelin (**SEQ ID NO: 1**)




(U.S. Patent No. 4,024,248, German Patent No. 2438352, JP-A 51-41359);

(2) Triptorelin (**SEQ ID NO: 2**)




(U.S. Patent No. 4010125, JP-A 52-31073);

(3) Nafarelin (**SEQ ID NO: 3**)




(U.S. Patent No. 4234571, JP-A 55-164663, JP-A 63-264498, JP-A 64-25794);

(4) Histrelin (**SEQ ID NO: 4**)




(5) Deslorelin (**SEQ ID NO: 5**)




(U.S. Patent Nos. 4569967 and 4218439);

(6) Meterelin (**SEQ ID NO: 6**)




(WO 91/18016);

(7) Gonadorelin (**SEQ ID NO: 7**)




(German Patent No. 2213737);

(8) Goserelin (**SEQ ID NO: 8**)



(U.S. Patent No. 4100274, JP-A 52-136172);

(9) Lecirelin



(Belgium Patent No. 897455, JP-A 59-59654); and salts thereof.